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The paper in this issue by Tra et al. [5] addresses imple-
mentation. The design of this study has been published 
separately [6]. The authors report a large retrospective 
observation on adherence to European Society of Cardiol-
ogy (ESC) guidelines on preventive medication after ACSs 
[7]. In the 13 (out of 91) medical centres in the Nether-
lands that were randomly selected for the analysis, overall 
adherence to guideline-recommended preventive medica-
tion was acceptable, with complete adherence to the five 
recommended classes of drugs in almost 70 % of the 2471 
patients in the analysis. This proportion may in fact be 
underestimated, for several reasons. First, at discharge 
not all long-term medication may have been initiated. In 
particular, blood pressure lowering medication should be 
titrated to blood pressure and to patient tolerance. Grad-
ual increases in drug therapy would be prudent, particu-
larly in the 50 % of the patients in the study who were not 
classified as hypertensive. Second, no information on left 
ventricular function is presented. Patients with preserved 
ejection fraction and no other indication for renin-angio-
tensin-aldosterone system (RAAS) blocking agents (such 
as diabetes) may be managed without RAAS blockers, as 
per ESC guidelines. Third, angiotensin receptor-blocking 
agents may have been used in patients who do not tolerate 
ACE inhibitors. This was not recorded in the study, as the 
authors report, but should be considered as adherence to 
the guidelines.
Several limitations need to be considered. The propor-
tion of patients who reached the target levels for blood pres-
sure, low-density lipoprotein cholesterol, glucose or HbA1c 
was not reported. Mere initiation of medication is not suf-
ficient for achieving the full potential of prevention. Sec-
ond, lifestyle risk factors are not addressed in the analysis. 
Clearly, smoking, physical activity and weight management 
should be addressed, even during the hospital phase. With 
Recurrent ischaemic events are common in patients dis-
charged after an acute coronary syndrome (ACS). In a 
large observational study in 16,321 patients, 20 % were 
rehospitalised and 18 % of the men and 23 % of the women 
older than 40 years died in the first year following dis-
charge [1].
Adequate secondary prevention after ACS may save at 
least as many lives as treatment provided during the acute 
phase [2, 3]. Equally important as preventive medication, 
improvements in lifestyle-related risk factors will result in 
significant risk reductions. In the OASIS-5 trial, patients 
with non-ST-segment elevation (STE) ACS were encour-
aged to adhere to a healthy diet, regular physical activ-
ity and smoking cessation. Patients who adhered to both 
diet and exercise had a relative risk reduction (RRR) of 
54 % for myocardial infarction (MI), stroke or death (odds 
ratio (OR) 0.46; 95 % confidence interval (CI) 0.38–0.57; 
p = 0.0001), and for those who gave up smoking a RRR of 
43 % for MI (OR 0.57; 95 % CI 0.36–0.89; p<0.0145) [4].
Written guidelines in medicine have been in use for 
thousands of years. However, their nature and status 
have changed substantially in recent years. Most impor-
tantly, they are now based primarily on evidence, as 
opposed to authority or tradition, and they now have 
a major legal and financial impact. In spite of substan-
tial experience with guidelines in medicine, important 
issues remain, ranging from how to select members of 
the writing group to challenges with implementation in 
clinical practice.
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no information in these aspects, even complete adherence to 
medication should not be seen as evidence of good overall 
adherence to the guideline. Third, oral anticoagulants are 
not considered in the analysis, although they would clearly 
impact on preventive drug selection. Fourth, the prescrip-
tion of drugs that are in fact not indicated or contraindicated 
(e.g. beta blockers in patients with severe asthma) should 
have been part of the analysis since this may be classified as 
non-adherence.
Although the findings in the study may therefore not be 
quantitatively accurate, they do provide a useful estimate. 
They may be used to rank medical centres according to 
adherence and to selectively address those where improve-
ments would be most desirable. This may be accomplished 
by feedback and benchmarking. Advice could be tailored, 
depending on specific issues per centre.
The involvement of nurses and nurse-led clinics may be 
considered. Important improvements in guideline adher-
ence have been documented in randomised trials [8]. 
Preventive medicine requires discipline from healthcare 
providers, and this may not be a field where physicians out-
perform others.
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